Retinoblastoma Chemotherapies at CIOC 2027

Retinoblastoma, a rare childhood eye cancer, presents unique challenges in chemotherapy due to its location and age of onset. Chemotherapy regimens for retinoblastoma typically involve a combination of drugs to target the rapidly dividing cancer cells. Topotecan and carboplatin are commonly used in systemic chemotherapy, often administered intravenously. These drugs work by interfering with DNA replication and cell division, thereby halting the growth of cancerous cells. Additionally, intra-arterial chemotherapy directly delivers high doses of chemotherapy drugs to the eye through the ophthalmic artery, minimizing systemic side effects. Emerging therapies such as targeted molecular agents hold promise for more effective and less toxic treatments. As research advances, personalized approaches tailored to individual patients' genetic profiles may further enhance treatment outcomes in retinoblastoma.